Aptevo Therapeutics Inc (NASDAQ:APVO) Director Fuad El-Hibri bought 18,919 shares of Aptevo Therapeutics stock in a transaction dated Wednesday, July 10th. The stock was acquired at an average price of $0.85 per share, for a total transaction of $16,081.15. Following the completion of the acquisition, the director now owns 843,455 shares in the company, valued at $716,936.75. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.
Shares of NASDAQ:APVO opened at $0.86 on Friday. Aptevo Therapeutics Inc has a 12 month low of $0.67 and a 12 month high of $5.80. The firm’s 50-day moving average price is $0.83. The company has a debt-to-equity ratio of 0.60, a quick ratio of 2.91 and a current ratio of 3.15.
Aptevo Therapeutics (NASDAQ:APVO) last issued its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.44) EPS for the quarter, meeting the consensus estimate of ($0.44). The company had revenue of $7.02 million for the quarter, compared to the consensus estimate of $6.30 million. Aptevo Therapeutics had a negative net margin of 199.24% and a negative return on equity of 122.33%. On average, equities analysts forecast that Aptevo Therapeutics Inc will post -1.4 EPS for the current year.
APVO has been the topic of several analyst reports. Piper Jaffray Companies upped their price target on shares of Aptevo Therapeutics from $4.00 to $4.50 and gave the company an “overweight” rating in a report on Monday, April 15th. ValuEngine downgraded shares of Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Zacks Investment Research downgraded shares of GENEL ENERGY PL/ADR from a “hold” rating to a “sell” rating in a report on Thursday, July 4th. Finally, Roth Capital reiterated a “buy” rating on shares of Resverlogix in a report on Thursday, May 23rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $7.88.
A number of large investors have recently modified their holdings of APVO. Marshall Wace LLP acquired a new position in Aptevo Therapeutics during the 1st quarter worth about $33,000. Deutsche Bank AG lifted its holdings in Aptevo Therapeutics by 251.7% during the 4th quarter. Deutsche Bank AG now owns 330,200 shares of the biotechnology company’s stock worth $419,000 after buying an additional 236,300 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in Aptevo Therapeutics by 1.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,442,049 shares of the biotechnology company’s stock worth $1,831,000 after buying an additional 16,482 shares during the period. Institutional investors own 36.37% of the company’s stock.
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations.
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.